Source comparison
Ipamorelin Acetate: Growth Hormone Peptide Comparison
Below is a direct comparison of ipamorelin acetate against other commonly used growth hormone secretagogues. Each peptide's receptor selectivity, side effect profile, and typical research applications are outlined to guide protocol selection. Ipamorelin Acetat
This comparison does not assign a generated winner or score.
- Below is a direct comparison of ipamorelin acetate against other commonly used growth hormone secretagogues. Each peptide's receptor selectivity, side effect profile, and typical research applications are outlined to guide protocol selection.
- Ipamorelin Acetate
- GHS-R1a agonist (ghrelin receptor)
- ~2 hours
- None
- Metabolic studies, body composition, sleep GH pulsatility
- Most selective ghrelin mimetic. Zero cortisol or prolactin elevation. Ideal for protocols requiring physiological GH patterns without confounding hormonal changes.
- GHRP-6
- GHS-R1a agonist (non-selective)
- Mild (10–20%)
- Significant (30–50% intake increase)
- Early GH research, appetite signaling studies
- Strong GH release but appetite stimulation makes it unsuitable for calorie-controlled metabolic studies. Use only when hunger pathway investigation is part of the protocol.
- GHRP-2
- GHS-R1a agonist (partial selectivity)
- Moderate (25–40%)
- Mild (10–15% intake increase)
- Body composition, athletic recovery
- Balanced profile. Stronger GH output than ipamorelin but cortisol elevation limits use in stress-sensitive models.
- Hexarelin
- GHS-R1a agonist (high potency, non-selective)
- High (40–60%)
- Moderate
- Cardiac studies, extreme GH output research
- Highest GH output but significant cortisol surge and cardiac hypertrophy risk in chronic use. Not suitable for long-term protocols.
- CJC-1295 (no DAC)
- GHRH receptor agonist
- ~30 minutes
- Synergistic GH protocols (combined with ghrelin mimetics)
- Works through GHRH pathway. Produces moderate GH release alone, synergistic effect when paired with ipamorelin. No selectivity issues since it does not act on ghrelin receptors.
- MK-677 (Ibutamoren)
- Oral GHS-R1a agonist
- ~24 hours
- Mild (sustained low-level elevation)
- Moderate to significant
- Oral administration studies, chronic GH elevation research
- Oral bioavailability advantage, but 24-hour half-life creates sustained GH elevation rather than pulsatile secretion. Receptor downregulation risk after 8–10 weeks.
- The key differentiation: ipamorelin acetate is the only ghrelin mimetic that produces robust GH release without elevating cortisol, prolactin, or appetite hormones. For any study where these variables must remain controlled, ipamorelin is the only viable choice. When maximal GH output is the priority and cortisol elevation is acceptable, hexarelin or GHRP-2 may be considered. But the trade-off is loss of hormonal selectivity. For protocols requiring synergistic GH amplification, combining ipamorelin with CJC-1295 (no DAC) produces the highest GH peaks with preserved pulsatility and zero off-target effects.